FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2136451551> ?p ?o ?g. }

• W2136451551 endingPage "2369" @default.
• W2136451551 startingPage "2361" @default.
• W2136451551 abstract "Purpose We compared nab-paclitaxel or ixabepilone once per week to paclitaxel with bevacizumab as first-line therapy for patients with advanced breast cancer (BC) to evaluate progression-free survival (PFS) for nab-paclitaxel or ixabepilone versus paclitaxel. Patients and Methods Eligible patients were age ≥ 18 years with chemotherapy-naive advanced BC. Patients were randomly assigned to bevacizumab with paclitaxel 90 mg/m 2 (arm A), nab-paclitaxel 150 mg/m 2 (arm B), or ixabepilone 16 mg/m 2 (arm C), once per week for 3 of 4 weeks. Planned enrollment was 900 patients, which would give 88% power to detect a hazard ratio of 0.73. Results In all, 799 patients were enrolled, and 783 received treatment (97% received bevacizumab). Arm C was closed for futility at the first interim analysis (n = 241), and arm A (n = 267) and arm B (n = 275) were closed for futility at the second interim analysis. Median PFS for paclitaxel was 11 months, ixabepilone was inferior to paclitaxel (PFS, 7.4 months; hazard ratio, 1.59; 95% CI, 1.31 to 1.93; P < .001), and nab-paclitaxel was not superior to paclitaxel (PFS, 9.3 months; hazard ratio, 1.20; 95% CI, 1.00 to 1.45; P = .054). Results were concordant with overall survival; time to treatment failure was significantly shorter in both experimental arms v paclitaxel. Hematologic and nonhematologic toxicity, including peripheral neuropathy, was increased with nab-paclitaxel, with more frequent and earlier dose reductions. Conclusion In patients with chemotherapy-naive advanced BC, ixabepilone once per week was inferior to paclitaxel, and nab-paclitaxel was not superior with a trend toward inferiority. Toxicity was increased in the experimental arms, particularly for nab-paclitaxel. Paclitaxel once per week remains the preferred palliative chemotherapy in this setting." @default.
• W2136451551 created "2016-06-24" @default.
• W2136451551 creator A5001268619 @default.
• W2136451551 creator A5019199541 @default.
• W2136451551 creator A5027821205 @default.
• W2136451551 creator A5044773708 @default.
• W2136451551 creator A5047713528 @default.
• W2136451551 creator A5052268581 @default.
• W2136451551 creator A5065306642 @default.
• W2136451551 creator A5070245248 @default.
• W2136451551 creator A5073728088 @default.
• W2136451551 creator A5075662505 @default.
• W2136451551 creator A5077437003 @default.
• W2136451551 creator A5084530547 @default.
• W2136451551 creator A5090188675 @default.
• W2136451551 date "2015-07-20" @default.
• W2136451551 modified "2023-10-11" @default.
• W2136451551 title "Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)" @default.
• W2136451551 cites W1605523334 @default.
• W2136451551 cites W1946819517 @default.
• W2136451551 cites W1966903548 @default.
• W2136451551 cites W1974811976 @default.
• W2136451551 cites W1978138543 @default.
• W2136451551 cites W1987825026 @default.
• W2136451551 cites W1991070664 @default.
• W2136451551 cites W1995809342 @default.
• W2136451551 cites W2000967612 @default.
• W2136451551 cites W2015294539 @default.
• W2136451551 cites W2019108567 @default.
• W2136451551 cites W2020026210 @default.
• W2136451551 cites W2064087555 @default.
• W2136451551 cites W2076811098 @default.
• W2136451551 cites W2078118820 @default.
• W2136451551 cites W2102826942 @default.
• W2136451551 cites W2112901840 @default.
• W2136451551 cites W2118881636 @default.
• W2136451551 cites W2126275851 @default.
• W2136451551 cites W2136791645 @default.
• W2136451551 cites W2140837341 @default.
• W2136451551 cites W2147081651 @default.
• W2136451551 cites W2149783819 @default.
• W2136451551 cites W2150296977 @default.
• W2136451551 cites W2153017356 @default.
• W2136451551 cites W2164934025 @default.
• W2136451551 cites W2169961966 @default.
• W2136451551 cites W2219978888 @default.
• W2136451551 cites W2326021992 @default.
• W2136451551 cites W2410755836 @default.
• W2136451551 cites W26458869 @default.
• W2136451551 cites W4293241248 @default.
• W2136451551 doi "https://doi.org/10.1200/jco.2014.59.5298" @default.
• W2136451551 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4500830" @default.
• W2136451551 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26056183" @default.
• W2136451551 hasPublicationYear "2015" @default.
• W2136451551 type Work @default.
• W2136451551 sameAs 2136451551 @default.
• W2136451551 citedByCount "169" @default.
• W2136451551 countsByYear W21364515512012 @default.
• W2136451551 countsByYear W21364515512014 @default.
• W2136451551 countsByYear W21364515512015 @default.
• W2136451551 countsByYear W21364515512016 @default.
• W2136451551 countsByYear W21364515512017 @default.
• W2136451551 countsByYear W21364515512018 @default.
• W2136451551 countsByYear W21364515512019 @default.
• W2136451551 countsByYear W21364515512020 @default.
• W2136451551 countsByYear W21364515512021 @default.
• W2136451551 countsByYear W21364515512022 @default.
• W2136451551 countsByYear W21364515512023 @default.
• W2136451551 crossrefType "journal-article" @default.
• W2136451551 hasAuthorship W2136451551A5001268619 @default.
• W2136451551 hasAuthorship W2136451551A5019199541 @default.
• W2136451551 hasAuthorship W2136451551A5027821205 @default.
• W2136451551 hasAuthorship W2136451551A5044773708 @default.
• W2136451551 hasAuthorship W2136451551A5047713528 @default.
• W2136451551 hasAuthorship W2136451551A5052268581 @default.
• W2136451551 hasAuthorship W2136451551A5065306642 @default.
• W2136451551 hasAuthorship W2136451551A5070245248 @default.
• W2136451551 hasAuthorship W2136451551A5073728088 @default.
• W2136451551 hasAuthorship W2136451551A5075662505 @default.
• W2136451551 hasAuthorship W2136451551A5077437003 @default.
• W2136451551 hasAuthorship W2136451551A5084530547 @default.
• W2136451551 hasAuthorship W2136451551A5090188675 @default.
• W2136451551 hasBestOaLocation W21364515511 @default.
• W2136451551 hasConcept C121608353 @default.
• W2136451551 hasConcept C126322002 @default.
• W2136451551 hasConcept C141071460 @default.
• W2136451551 hasConcept C143998085 @default.
• W2136451551 hasConcept C168563851 @default.
• W2136451551 hasConcept C203092338 @default.
• W2136451551 hasConcept C207103383 @default.
• W2136451551 hasConcept C2775930923 @default.
• W2136451551 hasConcept C2776694085 @default.
• W2136451551 hasConcept C2777292972 @default.
• W2136451551 hasConcept C2777802072 @default.
• W2136451551 hasConcept C2779194965 @default.
• W2136451551 hasConcept C44249647 @default.
• W2136451551 hasConcept C530470458 @default.
• W2136451551 hasConcept C61943457 @default.

• next